Apellis Stock Analysis

APLS Stock  USD 52.61  0.00  0.00%   
Apellis Pharmaceuticals price fall over the last few months could raise concerns from retail investors as the firm is trading at a share price of 52.61 on 503,956 in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in December. However, diversifying your holdings with Apellis Pharmaceuticals or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.11. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Apellis Pharmaceuticals partners.
Please continue to Trending Equities.
  
The Apellis Pharmaceuticals stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Apellis Pharmaceuticals is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, Christmas Day ( substitute day ), New Year 's Monday, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. Apellis Stock trading window is adjusted to America/New York timezone. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Apellis Pharmaceuticals' ongoing operational relationships across important fundamental and technical indicators.

Apellis Stock Analysis Notes

About 15.0% of the company shares are held by company insiders. The company recorded a loss per share of 7.87. Apellis Pharmaceuticals had not issued any dividends in recent years. Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts. Apellis Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 476 people. For more info on Apellis Pharmaceuticals please contact Cedric Francois at 617 977 5700 or go to https://www.apellis.com.

Apellis Pharmaceuticals Upcoming and Recent Events

Earnings reports are used by Apellis Pharmaceuticals to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apellis Pharmaceuticals previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report27th of April 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Apellis Pharmaceuticals SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Apellis Pharmaceuticals prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Apellis Pharmaceuticals investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Apellis Pharmaceuticals specific information freely available to individual and institutional investors to make a timely investment decision.
24th of August 2022
Other Events
View
2nd of August 2022
Financial Statements and Exhibits. Other Events. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
27th of July 2022
Financial Statements and Exhibits. Unregistered Sales of Equity Securities. Entry into a Material Definitive Agreement
View
19th of July 2022
Other Events
View
2nd of June 2022
Submission of Matters to a Vote of Security Holders
View

Apellis Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Apellis Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Apellis Pharmaceuticals backward and forwards among themselves. Apellis Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Apellis Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares11.5 K786 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares10.4 K471 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares11.6 K591 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares13.7 K646 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.3 K241 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.3 K462 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares7.2 K310 K
Note, although Apellis Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Apellis Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 5.84 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Apellis Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Apellis Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Apellis Profitablity

Apellis Pharmaceuticals' profitability indicators refer to fundamental financial ratios that showcase Apellis Pharmaceuticals' ability to generate income relative to its revenue or operating costs. If, let's say, Apellis Pharmaceuticals is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Apellis Pharmaceuticals' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Apellis Pharmaceuticals' profitability requires more research than a typical breakdown of Apellis Pharmaceuticals' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2023
Return on Investment(129.69) (139.93) 
Return on Average Assets(93.18) (100.53) 
Return on Average Equity(425.73) (459.34) 
Return on Invested Capital(1.19) (1.22) 
Return on Sales(9.91) (10.17) 

Management Efficiency

The entity has return on total asset (ROA) of (0.4647) % which means that it has lost $0.4647 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.0711) %, meaning that it created substantial loss on money invested by shareholders. Apellis Pharmaceuticals management efficiency ratios could be used to measure how well apellis pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 01/27/2023, Return on Investment is likely to drop to -139.93. In addition to that, Return on Average Assets is likely to drop to -100.53. Apellis Pharmaceuticals Tangible Asset Value is relatively stable at the moment as compared to the past year. Apellis Pharmaceuticals reported last year Tangible Asset Value of 1.01 Billion
Last ReportedProjected for 2023
Book Value per Share 2.12  2.81 
Enterprise Value over EBIT(6.90) (7.44) 
Enterprise Value over EBITDA(6.38) (6.88) 
Price to Book Value 23.89  25.43 
Tangible Assets Book Value per Share 12.01  10.97 
Enterprise Value4.7 B3.8 B
Tangible Asset ValueB1.1 B
Non Current Liabilities Total
551.3 M
Short Long Term Debt Total
210.2 M
Interest Expense
13.2 M
Total Operating Expenses
597.6 M
Beta
1.2264

Technical Drivers

As of the 27th of January, Apellis Pharmaceuticals shows the risk adjusted performance of (0.024393), and Mean Deviation of 2.6. Apellis Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Apellis Pharmaceuticals, which can be compared to its rivals. Please confirm Apellis Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Apellis Pharmaceuticals is priced correctly, providing market reflects its regular price of 52.61 per share. Given that Apellis Pharmaceuticals has jensen alpha of (0.25), we suggest you to validate Apellis Pharmaceuticals's prevailing market performance to make sure the company can sustain itself at a future point.

Apellis Pharmaceuticals Price Movement Analysis

Execute Study
The output start index for this execution was fourty-eight with a total number of output elements of thirteen. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Apellis Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Apellis Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Apellis Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apellis Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apellis Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apellis Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
David Watson 3 days ago
Payment of 2034 shares by David Watson of Apellis Pharmaceuticals subject to Rule 16b-3
David Watson over a week ago
Acquisition by David Watson of 24003 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Pascal Deschatelets over three months ago
Exercise or conversion by Pascal Deschatelets of 18500 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Adam Townsend over three months ago
Exercise or conversion by Adam Townsend of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Alec Machiels over three months ago
Exercise or conversion by Alec Machiels of 1250 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Pascal Deschatelets over three months ago
Exercise or conversion by Pascal Deschatelets of 18500 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over three months ago
Apellis Pharmaceuticals exotic insider transaction detected
Adam Townsend over three months ago
Exercise or conversion by Adam Townsend of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Federico Grossi over three months ago
Sale by Federico Grossi of 2500 shares of Apellis Pharmaceuticals
Chopas James George over three months ago
Payment of 558 shares by Chopas James George of Apellis Pharmaceuticals subject to Rule 16b-3
Dunlop A Sinclair over three months ago
Exercise or conversion by Dunlop A Sinclair of 4306 shares of Apellis Pharmaceuticals subject to Rule 16b-3
Delong Mark Jeffrey over three months ago
Exercise or conversion by Delong Mark Jeffrey of 5000 shares of Apellis Pharmaceuticals subject to Rule 16b-3

Apellis Pharmaceuticals Predictive Daily Indicators

Apellis Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Apellis Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Apellis Pharmaceuticals Forecast Models

Apellis Pharmaceuticals time-series forecasting models is one of many Apellis Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Apellis Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Apellis Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Apellis Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Apellis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Apellis Pharmaceuticals. By using and applying Apellis Stock analysis, traders can create a robust methodology for identifying Apellis entry and exit points for their positions.
Last ReportedProjected for 2023
Operating Margin(76.74) (82.80) 
Gross Margin 89.73  89.21 

Current Apellis Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Apellis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Apellis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
69.14Buy14Odds
Apellis Pharmaceuticals current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Apellis analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Apellis stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Apellis Pharmaceuticals, talking to its executives and customers, or listening to Apellis conference calls.
Apellis Analyst Advice Details

Apellis Stock Analysis Indicators

Apellis Pharmaceuticals stock analysis indicators help investors evaluate how Apellis Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Apellis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Apellis Pharmaceuticals stock analysis, traders can identify Apellis Pharmaceuticals position entry and exit signals to maximize returns.
Begin Period Cash Flow567 M
Common Stock Shares Outstanding75.2 M
Total Stockholder Equity198.7 M
Total Cashflows From Investing Activities247.6 M
Tax Provision352 K
Property Plant And Equipment Net26.1 M
Retained Earnings-1.7 B
Cash And Short Term Investments700.5 M
Cash640.2 M
Accounts Payable16.9 M
Net Debt-430 M
50 Day M A49.973
Total Current Liabilities131.8 M
Other Operating Expenses602.8 M
Non Current Assets Total57.7 M
Non Currrent Assets Other31.6 M
Please continue to Trending Equities. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for analysis

When running Apellis Pharmaceuticals price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Is Apellis Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apellis Pharmaceuticals. If investors know Apellis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apellis Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.8 B
Quarterly Revenue Growth
2.904
Return On Assets
(0.46) 
Return On Equity
(5.07) 
The market value of Apellis Pharmaceuticals is measured differently than its book value, which is the value of Apellis that is recorded on the company's balance sheet. Investors also form their own opinion of Apellis Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Apellis Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apellis Pharmaceuticals' market value can be influenced by many factors that don't directly affect Apellis Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apellis Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Apellis Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apellis Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.